Vida Health has announced the expansion of its clinical portfolio to include care for patients living with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease closely linked to obesity and related cardiometabolic conditions. The new offering integrates obesity treatment, lifestyle modification, behavioral health support and longitudinal coaching within the company’s virtual care model.
MASH affects an estimated 5% of U.S. adults and is associated with obesity, type 2 diabetes, dyslipidemia and hypertension. Following recent FDA approval of GLP-1 medications for noncirrhotic MASH with moderate to advanced liver fibrosis, employers and health plans face new considerations around patient identification, long-term management and pharmacy spend.
Vida’s expanded program is designed to complement specialist care delivered by hepatologists, endocrinologists and obesity medicine physicians. Through its telehealth platform, Vida provides structured, evidence-based interventions that include comprehensive lifestyle changes, behavioral health services and medication management, with GLP-1 prescribing used when medically appropriate.
“Obesity is a common thread connecting many of the most costly and complex chronic conditions employers and health plans face today,” said Joe Murad, CEO at Vida Health. “By expanding our obesity care model to include support for people living with MASH, Vida is providing a whole-person approach to help members improve their health, while helping our partners manage GLP-1 spend and patient treatments.”
Vida assesses each patient’s risk factors, health history and prior obesity treatments to develop personalized, clinically validated care plans. The model emphasizes responsible prescribing and prioritizes lifestyle and lower-cost therapeutic interventions when suitable. According to the company, this approach supports sustained weight loss and may help slow or prevent MASH progression.
For employers and health plans, Vida positions the MASH expansion as an extension of its broader cardiometabolic strategy, which aims to balance clinical outcomes with cost management. The company reports experience in GLP-1 spend trend mitigation and highlights its value-based pricing model focused on measurable outcomes.
Vida operates nationwide across all 50 states and Washington, D.C., delivering services in English and Spanish. The addition of MASH support reflects the growing focus among virtual care providers on addressing obesity-related comorbidities as part of integrated, longitudinal care models.
Click here for the original news story.